Abstract
Background
Perioperative venothromboembolism (VTE) chemoprophylaxis is an established tenant of bariatric surgery; however, there is little comparative data to guide medication choice. The objective of this study was to determine if a change in VTE prophylaxis from heparin to enoxaparin was associated with differing rates of postoperative bleeding and VTE occurrence after bariatric surgery.
Methods
This retrospective cohort study included patients 18 years or older who underwent primary bariatric surgery (sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB)) at a single institution between March 2012 and December 2021. Subcutaneous unfractionated heparin was utilized for VTE prophylaxis from March 2012 through February 2018 and then enoxaparin was used from March 2018 through December 2021. Postoperative bleeding was defined as requiring a blood transfusion or reoperation for bleeding within 30 days of surgery. Chi-square test was used to test for differences between groups.
Results
There were 2159 patients who underwent bariatric surgery with 1324 (61.3%) patients in the heparin group and 835 (38.7%) in the enoxaparin group. Overall, 1,503 (69.6%) patients underwent SG and 656 (30.4%) RYGB. There was no difference in the ratio of SG to RYGB between the heparin and enoxaparin groups. Most patients were female (n = 1709, 79.2%) with a median age of 43.2 years (interquartile range (IQR): 35.6–52.2), and median BMI of 44.9 (IQR: 40.9–50.5). Overall postoperative bleeding occurred more frequently in the enoxaparin group (n = 26, 3.1%) compared with the heparin group (n = 12, 0.9%) (p < 0.01). Additionally, reoperation for bleeding was more frequent with enoxaparin (enoxaparin 0.8% vs. heparin 0.2%, p = 0.04). There was no difference in VTE occurrence between the two groups (heparin: n = 14, 1.1%, enoxaparin: n = 7, 0.8% (p = 0.61)).
Conclusions
An institutional change from heparin to enoxaparin for bariatric surgery perioperative VTE prophylaxis was associated with a significant increase in postoperative bleeding, with no difference in VTE complications.
Similar content being viewed by others
References
Becattini C, Agnelli G, Manina G, Noya G, Rondelli F (2012) Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surg Obes Relat Dis 8(1):108–115. https://doi.org/10.1016/J.SOARD.2011.09.005
Imberti D, Baldini E, Pierfranceschi MG et al (2014) Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX study). Obes Surg 24(2):284–291. https://doi.org/10.1007/S11695-013-1105-X
Aminian A, Andalib A, Khorgami Z et al (2017) Who should get extended thromboprophylaxis after bariatric surgery?: A risk assessment tool to guide indications for post-discharge pharmacoprophylaxis. Ann Surg 265(1):143–150. https://doi.org/10.1097/SLA.0000000000001686
Finks JF, English WJ, Carlin AM et al (2012) Predicting risk for venous thromboembolism with bariatric surgery: results from the michigan bariatric surgery collaborative. Ann Surg 255(6):1100–1104. https://doi.org/10.1097/SLA.0B013E31825659D4
Nimeri AA, Bautista J, Ibrahim M et al (2018) Mandatory risk assessment reduces venous thromboembolism in bariatric surgery patients. Obes Surg 28(2):541–547. https://doi.org/10.1007/S11695-017-2909-X
Kruk ME, Pereira C, Vaz F, Bergstrom S, Galea S (2007) Economic evaluation of surgically trained assistant medical officers in performing major obstetric surgery in Mozambique. BJOG 114(10):1253–1260
Birkmeyer NJO, Finks JF, Carlin AM et al (2012) Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Arch Surg 147(11):994–998. https://doi.org/10.1001/ARCHSURG.2012.2298
Mukherjee D, Lidor AO, Chu KM, Gearhart SL, Haut ER, Chang DC (2008) Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surg 12(11):2015–2022. https://doi.org/10.1007/S11605-008-0600-1
Sapala JA, Wood MH, Schuhknecht MP, Sapala MA (2003) Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 13(6):819–825. https://doi.org/10.1381/096089203322618588
Morino M, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N (2007) Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 246(6):1002–1007. https://doi.org/10.1097/SLA.0B013E31815C404E
Hamad GG, Bergqvist D (2007) Venous thromboembolism in bariatric surgery patients: an update of risk and prevention. Surg Obes Relat Dis 3(1):97–102. https://doi.org/10.1016/J.SOARD.2006.10.002
Brethauer SA (2013) ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis 9(4):493–497. https://doi.org/10.1016/J.SOARD.2013.03.006
Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: american college of chest physicians evidence-based clinical practice guidelines (8TH Edition). Chest 133(6):381S-453S. https://doi.org/10.1378/CHEST.08-0656
Mehran A, Szomstein S, Zundel N, Rosenthal R (2003) Management of acute bleeding after laparoscopic Roux-en-Y gastric bypass. Obes Surg 6:842–847
Amanda Dick T, Byrne K, Baker M, Budak A, Morgan K (2010) Gastrointestinal bleeding after gastric bypass surgery: nuisance or catastrophe? Surg Obes Relat Dis. 6:643–647
Nielsen AW, Helm MC, Kindel T et al (2017) Perioperative bleeding and blood transfusion are major risk factors for venous thromboembolism following bariatric surgery. Surg Endosc 5:2488–2495
Li A, Eshaghpour A, Tseng E et al (2021) Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more. Thromb Res 198:1–6
Singh K, Podolsky ER, Um S et al (2012) Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 22(1):47–51. https://doi.org/10.1007/S11695-011-0397-Y
Fecso AB, Samuel T, Elnahas A et al (2018) Clinical indicators of postoperative bleeding in bariatric surgery. Surg Laparosc Endosc Percutan Tech 1:52–55
Bakhos C, Alkhoury F, Kyriakides T, Reinhold R, Nadzam G (2009) Early postoperative hemorrhage after open and laparoscopic roux-en-y gastric bypass. Obes Surg 19(2):153–157. https://doi.org/10.1007/S11695-008-9580-1/TABLES/2
Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program | ACS. Accessed February 9, 2023. https://www.facs.org/quality-programs/accreditation-and-verification/metabolic-and-bariatric-surgery-accreditation-and-quality-improvement-program/
Northwestern Medicine Enterprise Data Warehouse (NMEDW): Research: Feinberg School of Medicine: Northwestern University. Accessed March 16, 2023. https://www.feinberg.northwestern.edu/research/cores/units/edw.html
Kothari SN, Lambert PJ, Mathiason MA (2007) A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg. 194(6):709–711
Scholten DJ, Hoedema RM, Scholten SE (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12(1):19–24. https://doi.org/10.1381/096089202321144522
Kalfarentzos F, Stavropoulou F, Yarmenitis S et al (2001) Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 11(6):670–676. https://doi.org/10.1381/09608920160558588
Brotman DJ, Shihab HM, Prakasa KR et al (2013) pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surg 148(7):675–686. https://doi.org/10.1001/JAMASURG.2013.72
Chang CK, Higgins RM, Rein L, Peppard WJ, Herrmann DJ, Kindel T (2023) Effectiveness of body mass index-based prophylactic enoxaparin dosing in bariatric surgery patients. J Surg Res 287:168–175. https://doi.org/10.1016/J.JSS.2023.01.018
Acknowledgements
Author AJR is supported on a training grant by the National Cancer Institute. Surgical Multispecialty Access to Research in Residency Training (SMART) training grant [R38 CA245095].
Funding
Not applicable
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
None related to this project. Audra J. Reiter: Intuitive Surgical, one-time honorarium. Alexander P. Nagle: Baxter. Eric S. Hungness: Intuitive, Baxter, Boston Scientific, Olympus, Ethicon. Ezra N. Teitelbaum: Boston Scientific Education and Consulting. Joanne Prinz and Yan Li: none.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Reiter, A.J., Prinz, J., Li, Y. et al. Increased bleeding risk with enoxaparin venothromboembolism prophylaxis compared with heparin in patients undergoing bariatric surgery. Surg Endosc 37, 6983–6988 (2023). https://doi.org/10.1007/s00464-023-10219-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-023-10219-2